Entera Bio Ltd. Operating CF per Share

Operating CF per Share of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating CF per Share growth rates and interactive chart. Total operating cash flow in a period divided by the weighted average number of shares outstanding. A company with $100 million in operating cash flow and 10 million weighted average shares will have operating cash flow per share of $10.


Highlights and Quick Summary

  • Operating CF per Share for the quarter ending June 29, 2020 was -0.19 (a 31.39% increase compared to previous quarter)
  • Year-over-year quarterly Operating CF per Share increased by 40.45%
  • Annual Operating CF per Share for 2019 was -0.73 (a -40.37% decrease from previous year)
  • Annual Operating CF per Share for 2018 was -1.23 (a 22.19% increase from previous year)
  • Twelve month Operating CF per Share ending June 29, 2020 was -0.61 (a 13.38% increase compared to previous quarter)
  • Twelve month trailing Operating CF per Share decreased by -9.56% year-over-year
Trailing Operating CF per Share for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-0.61 -0.53 -0.73 -0.67
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating CF per Share of Entera Bio Ltd.

Most recent Operating CF per Shareof ENTX including historical data for past 10 years.

Interactive Chart of Operating CF per Share of Entera Bio Ltd.

Entera Bio Ltd. Operating CF per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -0.19 -0.15
2019 -0.26 -0.14 -0.18 -0.17 -0.73
2018 -0.15 -0.2 -0.61 -0.55 -1.23
2017 0.0 -1.01

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.